<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255043</url>
  </required_header>
  <id_info>
    <org_study_id>KY20200110-02</org_study_id>
    <nct_id>NCT04255043</nct_id>
  </id_info>
  <brief_title>Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon</brief_title>
  <acronym>ULTIMATE-III</acronym>
  <official_title>Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon Treatment for Denovo Lesions in High Bleeding Risk Patients: a Prospective, Multi-center, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-coated balloon (DCB) is an alternative choice for denovo lesions in coronary artery
      disease patients with high bleeding risk. Intravascular ultrasound (IVUS) can provide more
      details of coronary anatomy and stent implantation, overcoming a number of limitations of
      coronary angiography. However, the benefit of IVUS-guided DCB treatment has not been
      investigated. This study is designed to compare IVUS-guided and Angiography-guided DCB
      treatment for coronary denovo lesions in patients with high bleeding risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized controlled trial that aims to enroll 260
      patients with high bleeding risk.

      All patients with coronary denovo lesions suitable for DCB treatment will undergo 1:1
      randomization to either IVUS guidance or Angiography guidance using the Central Randomization
      System.

      All subjects will be screened according to the predefined inclusion and exclusion criteria
      per protocol. Data and images will be collected during the index procedure, and at the
      predefined 7-month coronary angiography follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will undergo 1:1 randomization to either IVUS or Angiography-guided DCB treatment for coronary denovo lesions in patients with high bleeding risk.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will remain blinded until the final study results released.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss (LLL) at 7 months after procedure</measure>
    <time_frame>7 months</time_frame>
    <description>LLL is defined as the difference between postprocedural minimal lumen diameter (MLD) minus MLD at the time of angiographic follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>TVF is defined as the composite of cardiac death, target-vessel myocardial infarction and ischemia-driven target-vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>IVUS-guided DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided DCB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS guidance</intervention_name>
    <description>IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment</description>
    <arm_group_label>IVUS-guided DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angiography guidance</intervention_name>
    <description>DCB (Sequent® Please) treatment</description>
    <arm_group_label>Angiography-guided DCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. De novo lesions, suitable for DCB treatment.

          2. Patients with high bleeding risk.

        Exclusion Criteria:

          1. Target lesion length &gt; 15mm.

          2. Severe calcified lesions.

          3. Left main disease.

          4. Ostial lesions.

          5. Three-vessel disease.

          6. Acute myocardial infarction within 48 hours.

          7. Target vessel received stent implantation.

          8. Hemodynamic instability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Jie Zhang, MD</last_name>
    <phone>025-52271350</phone>
    <email>jameszll@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Fei Gao, MD</last_name>
    <phone>025-52271350</phone>
    <email>gaoxiaofei2014@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Junjie Zhang</investigator_full_name>
    <investigator_title>Vice chief of the department of cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

